On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation

PURPOSE: The third-generation EGFR inhibitor, osimertinib, is the first mutant selective inhibitor that has received regulatory approval for the treatment of patients with EGFR-mutant lung cancer. Despite the development of highly selective third-generation inhibitors, acquired resistance remains a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Brown, Benjamin P., Zhang, Yun-Kai, Westover, David, Yan, Yingjun, Qiao, Huan, Huang, Vincent, Du, Zhenfang, Smith, Jarrod A., Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj, Bazhenova, Lyudmila, Schrock, Alexa B., Meiler, Jens, Lovly, Christine M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548651/
https://ncbi.nlm.nih.gov/pubmed/30796031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3829
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi